Metformin in the prevention of preeclampsia

Evaluation of the effectiveness of metformin in the prevention of preeclampsia in pregnant women at high risk of preeclampsia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230730058975N1

Enrollment

160

Registered

2023-08-12

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group: Metformin 500 mg tablets, produced by Iran Najo company, one daily from the 12th week of pregnancy. Intervention 2: Control group: No action or medicine.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: age 18 to 45 informed consent having risk factors for preeclampsia

Exclusion criteria

Exclusion criteria: underlying disease like diabetes

Design outcomes

Primary

Measure	Time frame
Preeclampsia. Timepoint: Every two weeks from the 12th week of pregnancy. Method of measurement: history taking and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactvida Behzadfar

Esfahan University of Medical Sciences

behzadfar_neda@yahoo.com+98 913 511 0976

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026